Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 159 results for fibrosis

  1. Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)

    Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    26 October 2016
    View recommendations

    Sections for TA413

  2. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

    Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.

    Technology appraisal guidance
    Last updated
    27 November 2013
    View recommendations

    Sections for TA75

  3. Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

    Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.

    Technology appraisal guidance
    Published
    25 November 2015
    View recommendations

    Sections for TA365

  4. Further research is recommended on:• the impact of magnetic resonance elastography (MRE) test results on decisions about care, such as the decision to do a liver biopsy, or on adherence to lifestyle interventions (see section 3.5 )• the test accuracy of MRE to assess the level of fibrosis or presence of cirrhosis compared with biopsy at thresholds specified by the company, or the prognostic ability of MRE to predict clinical outcomes (see section 3.20 ).

    interventions (see section 3.5 )• the test accuracy of MRE to assess the level of fibrosis or presence of cirrhosis compared with biopsy...

    Research recommendation
    Published
    3 February 2023

  5. Psychological assessment:- What is the most effective measure of psychological functioning to use as a test for thresholds of concern in people with cystic fibrosis?

    functioning to use as a test for thresholds of concern in people with cystic fibrosis? Any explanatory notes(if applicable) Why this is...

    Research recommendation
    Published
    18 October 2018

  6. Airway clearance techniques:- How effective are daily airway clearance techniques in maintaining lung function in infants and children with cystic fibrosis?

    techniques in maintaining lung function in infants and children with cystic fibrosis? Any explanatory notes(if applicable) Why this is...

    Research recommendation
    Published
    6 November 2018

  7. Soft-palate implants for simple snoring (IPG240)

    Evidence-based recommendations on soft-palate implants for simple snoring. This involves inserting implants into the soft palate of the mouth to make it stiffer and less likely to vibrate.

    Interventional procedures guidance
    Published
    28 November 2007
    View recommendations

    Sections for IPG240

  8. Non-invasive tests for diagnosing NASH:- Which non-invasive tests most accurately identify non-alcoholic steatohepatitis (NASH) in people with non-alcoholic fatty liver disease (NAFLD)?

    minority of people with NAFLD. It is thought to be the precursor of liver fibrosis, which is associated with morbidity and mortality. As...

    Research recommendation
    Published
    24 August 2016

  9. Living-donor lung transplantation for end-stage lung disease (IPG170)

    Evidence-based recommendations on living-donor lung transplantation for end-stage lung disease. This involves removing a lung from each of the two donors and replacing the recipient's lungs with the donor lungs.

    Interventional procedures guidance
    Published
    24 May 2006
    View recommendations

    Sections for IPG170

  10. Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 TS ID 10767

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372

    In development [GID-TA11430] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Taking a proportionate approach to technology appraisals

    Find out more about NICE's new proportionate approach to technology appraisals

  13. Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplant (IPG695)

    Evidence-based recommendations on ex-situ machine perfusion for extracorporeal preservation of lungs for transplant. This involves using a machine to deliver an oxygenated solution to a donor lung and keep it at normal body temperature until it can be transplanted.

    Interventional procedures guidance
    Published
    26 May 2021
    View recommendations

    Sections for IPG695

  14. Cyanoacrylate glue occlusion for varicose veins (IPG670)

    Evidence-based recommendations on cyanoacrylate glue occlusion for varicose veins. This involves injecting medical glue (cyanoacrylate) into a vein to close it with the aim of improving symptoms.

    Interventional procedures guidance
    Published
    4 March 2020
    View recommendations

    Sections for IPG670

  15. Radiofrequency ablation for symptomatic interdigital (Morton's) neuroma (IPG539)

    Evidence-based recommendations on radiofrequency ablation for symptomatic interdigital (Morton’s) neuroma. This involves using pulses of radiofrequency heat energy to damage the nerve, with the aim of reducing pain.

    Interventional procedures guidance
    Published
    16 December 2015
    View recommendations

    Sections for IPG539